Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study

Página do item simplificado
dc.contributor.authorSilva, Giovanni Faria [UNESP]
dc.contributor.authorVillela-nogueira, Cristiane A.
dc.contributor.authorMello, Carlos Eduardo Brandao
dc.contributor.authorSoares, Elza Cotrim
dc.contributor.authorCoelho, Henrique Sergio M.
dc.contributor.authorFerreira, Paulo Roberto Abrao
dc.contributor.authorRuiz, Fernando Jose Goes
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversidade Federal do Rio de Janeiro (UFRJ)
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionPontifícia Universidade Católica de São Paulo (PUC-SP)
dc.date.accessioned2014-09-30T18:18:30Z
dc.date.available2014-09-30T18:18:30Z
dc.date.issued2014-01-01
dc.description.abstractBackground: Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment. Methods: A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment. Results: 308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis. Conclusion: Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment.en
dc.description.affiliationUniversidade Estadual Paulista (UNESP) Botucatu School of Medicine
dc.description.affiliationUniversidade Federal do Rio de Janeiro
dc.description.affiliationUniversidade Estadual de Campinas
dc.description.affiliationUniversidade Federal de Sao Paulo
dc.description.affiliationPontificia Universidade Catolica de Sao Paulo
dc.description.affiliationUnespUniversidade Estadual Paulista (UNESP) Botucatu School of Medicine
dc.format.extent48-52
dc.identifierhttp://dx.doi.org/10.1016/j.bjid.2013.05.007
dc.identifier.citationBrazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 18, n. 1, p. 48-52, 2014.
dc.identifier.doi10.1016/j.bjid.2013.05.007
dc.identifier.fileS1413-86702014000100048.pdf
dc.identifier.issn1413-8670
dc.identifier.lattes6322604200510676
dc.identifier.scieloS1413-86702014000100048
dc.identifier.urihttp://hdl.handle.net/11449/109595
dc.identifier.wosWOS:000332911100008
dc.language.isoeng
dc.publisherBrazilian Society of Infectious Diseases
dc.relation.ispartofBrazilian Journal of Infectious Diseases
dc.relation.ispartofjcr2.083
dc.relation.ispartofsjr0,817
dc.rights.accessRightsAcesso aberto
dc.sourceSciELO
dc.subjectHepatitis Cen
dc.subjectAdvanced fibrosisen
dc.subjectPeginterferonen
dc.subjectRibavirinen
dc.titlePeginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life studyen
dc.typeArtigo
unesp.author.lattes6322604200510676
unesp.author.orcid0000-0003-4858-2778[6]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
S1413-86702014000100048.pdf
Tamanho:
609.55 KB
Formato:
Adobe Portable Document Format
Baixar

Coleções

Artigos - Clínica Médica - FMB